Articles: pain.
-
Review Meta Analysis Comparative Study
Systematic review of observational (behavioral) measures of pain for children and adolescents aged 3 to 18 years.
Observational (behavioral) scales of pain for children aged 3 to 18 years were systematically reviewed to identify those recommended as outcome measures in clinical trials. This review was commissioned by the Pediatric Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials (www.immpact.org). In an extensive literature search, 20 observational pain scales were identified for review including behavior checklists, behavior rating scales, and global rating scales. ⋯ No observational measures were recommended for assessing chronic or recurrent pain because the overt behavioral signs of chronic pain tend to habituate or dissipate as time passes, making them difficult to observe reliably. In conclusion, no single observational measure is broadly recommended for pain assessment across all contexts. Directions for further research and scale development are offered.
-
Meta Analysis
Meta-analysis of cannabis based treatments for neuropathic and multiple sclerosis-related pain.
Debilitating pain, occurring in 50-70% of multiple sclerosis (MS) patients, is poorly understood and infrequently studied. We summarized efficacy and safety data of cannabinoid-based drugs for neuropathic pain. ⋯ This review was based on a small number of trials and patients. Pain related to MS was assumed to be similar to neuropathic pain.
-
Peroperative identification and subsequent division or preservation of the inguinal nerves during open hernia repair may influence the incidence of chronic postoperative pain. ⋯ The nerves should probably be identified during open hernia repair. Division of and preservation of the ilioinguinal nerve show similar results.
-
Anticonvulsant medicines have a place in the treatment of neuropathic pain (pain due to nerve damage). This review looks at the evidence for the pain relieving properties of lamotrigine. ⋯ Given the availability of more effective treatments including anticonvulsants and antidepressant medicines, lamotrigine does not have a significant place in therapy at present. The limited evidence currently available suggests that lamotrigine is unlikely to be of benefit for the treatment of neuropathic pain.
-
Cochrane Db Syst Rev · Jan 2007
Review Meta AnalysisSingle dose oral lumiracoxib for postoperative pain.
Lumiracoxib is a novel selective cyclooxygenase-2 (COX-2) inhibitor. COX-2 inhibitors have been developed to avoid COX-1 related gastrointestinal (GI) problems. Lumiracoxib has analgesic and anti-inflammatory activity comparable with traditional non-steroidal anti-inflammatory drugs (tNSAIDs) in the management of post-operative pain, but with the advantage of better GI tolerability. ⋯ Lumiracoxib 400 mg given as a single oral dose, is an effective analgesic for acute postoperative pain.